Stockwinners Market Radar for April 10, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 600K shares of Teladoc today

20:03 EDT Cathie Wood's ARK Investment bought 326K shares of Archer Aviation today

19:50 EDT Bon Natural Life Ltd trading halted, news pending

17:21 EDT Dell Technologies exec sells $12.5M in common stock - In a regulatory filing, Dell Technologies disclosed that its General Counsel Richard Rothberg sold 94K shares of common stock on April 8th in a total transaction size of $12.5M.

17:01 EDT Stewart acquires All New York Title Agency - Stewart Information Services "announced the acquisition of the All New York Title Agency, based in White Plains, New York. Founded in 1995 by Joseph Petrillo and John Martin, All New York has been one of the leading commercial boutique title companies, serving Affordable Housing, Supportive Housing and Senior Housing clients throughout New York State, in addition to relationships in the residential, condominium and multifamily markets."

16:33 EDT Cellectis publishes new research paper in Molecular Therapy - Cellectis announced the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells, or HSPCs, enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain. The CD11b intron-specific gene insertion approach efficiently restricts the expression of a desired transgene to the myeloid lineage, preventing its overexpression by stem cells or by other differentiated lineages. The insertion of an IDUA transgene in the first intron of the CD11b gene enables to express IDUA (the enzyme missing in Mucopolysaccharidosis type I patients), in a myeloid-specific manner without affecting CD11b endogenous expression. Edited HSPC exhibited robust engraftment in the bone marrow of immunodeficient mice, displayed multi-lineage differentiation in various hematopoietic tissues and showed significant presence in the brain as myeloid cells.

16:30 EDT Rent The Runway jumps 61% to $11.89 after Q4 results and guidance

16:28 EDT California Water Service confirms position to meet EPA PFAS compliance timeline - Following the U.S. Environmental Protection Agency's, or EPA, adoption of a new National Primary Drinking Water Regulation for certain per- and polyfluoroalkyl substances, or PFAS, California Water Service Group, or Group, confirmed that it believes its subsidiaries are well positioned to treat potentially impacted water sources and to meet the EPA's five-year compliance timeline. Under the new PFAS regulation, EPA established maximum contaminant levels of 4 parts per trillion, or ppt, for both PFOA and PFOS; MCLs of 10 ppt for PFHxS, PFNA, and GenX; and a combined Hazard Index of 1.0 for PFBS, PFHxS, PFNA, and GenX. Generally, PFAS are manmade compounds that are found in a number of everyday products; these compounds are soluble in water and can travel long distances. Under the new PFAS regulation, water utilities with impacted water systems across the country are required to monitor for these PFAS by 2027 and to comply with the MCLs and Hazard Index by 2029.

16:26 EDT DOJ files false claims act complaint against Regeneron over drug pricing - The United States filed a complaint under the False Claims Act against Regeneron Pharmaceuticals. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision. The complaint alleges that Regeneron fraudulently inflated Medicare reimbursement rates for Eylea by knowingly submitting false average sales price reports to the Centers for Medicare and Medicaid Services that excluded certain price concessions. In particular, the United States alleges that Regeneron knowingly failed to report price concessions in the form of credit card processing fees that Regeneron paid to specialty drug distributors to benefit its customers. According to the complaint, Regeneron paid these credit card fees so that distributors would accept credit cards for Eylea purchases while still charging a lower, cash price for the drug, and so that Regeneron's customers - typically retina and ophthalmic practices - could receive credit card benefits for their purchases, such as "cash back" and other credit card rewards. "We will not permit pharmaceutical companies to flout price reporting requirements to maintain high drug prices," said Principal Deputy Attorney General Brian M. Boynton, head of the Justice Department's Civil Division. "The department is committed to protecting federal health care programs from improper actions by drug companies or others that drive up the cost of those programs at the taxpayers' expense." Reference Link

16:23 EDT Neogen CEO buys $284K in common stock, CFO buys $156K in common stock - In a regulatory filing, Neogen disclosed that its CEO John Adent bought 23K shares of common stock and CFO Daid Naemura bought 12.5K shares of common stock on April 10th in total transaction sizes of $284K and $156K respectively.

16:21 EDT Costco reports March comparable sales up 7.7% - Reports March revenue $23.48B. Reports March e-commerce sales up 28.3%. This year's retail month of March was impacted by the shift in timing of Easter. The shift positively impacted total and comparable sales by approximately one-half percent.

16:19 EDT Sight Sciences publishes results from MIGS study in AJO - Sight Sciences announced the results as published in the American Journal of Ophthalmology, or AJO, International of the large scale, comparative real-world clinical outcomes study of patients treated by three minimally invasive glaucoma surgery, or MIGS, technologies. Using the American Academy of Ophthalmology IRIS Registry, this large-scale MIGS study evaluated long-term two-year post-surgical outcomes among patients with primary open-angle glaucoma, or POAG, treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices in the U.S. combined with cataract surgery, as well as for cataract surgery alone. OMNI facilitates an implant-free, ab interno procedure that addresses the three primary areas of resistance in the conventional outflow pathway. OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. At 24 months, high baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and the greatest numerical reduction in medication use. At 24 months, low baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and a statistically significantly greater mean medication use reduction compared to all other treatment groups.

16:15 EDT Bio-Rad COO Andrew Last to retire - Bio-Rad Laboratories announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a search for his successor. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences. "Andy's extensive operations experience, technical acumen, and leadership abilities have been invaluable to Bio-Rad over the past five years," said Norman Schwartz, Bio-Rad President and CEO. "We have made significant progress on our transformational objectives, including cost structure, core processes, and supply chain improvements, while effectively navigating various macroeconomic challenges."

16:10 EDT Terns Pharmaceuticals appoints Melita Sun Jung as chief business officer - Terns Pharmaceuticals announced the appointment of Melita Sun Jung as chief business officer, effective April 22. Jung joins Terns with more than 20 years of experience in the life sciences industry, leading corporate strategy and business development, commercial planning and execution, financings and investment management. Most recently, she served as chief business officer at Structure Therapeutics.

16:08 EDT Barrett Business announces board approval for four-for-one stock split - Barrett Business announced that its board of directors has approved a future four-for-one split of the company's common stock in the form of a stock dividend. The planned stock split is subject to stockholder approval of an amendment to the company's charter to increase the number of authorized shares of common stock from 20,500,000 to 82,000,000, which is proportionate to the anticipated future increase in the number of issued shares of common stock following the planned four-for-one stock split. The charter amendment will be submitted for stockholder approval at the upcoming annual meeting on June 3. Following stockholder approval, the company plans to announce the timing of the stock split and declare the stock dividend.

16:07 EDT Floor & Decor announces grand opening of first store in Augusta, GA - Floor & Decor announced the grand opening of its first warehouse location in Augusta, at 110 Mason McKnight Jr Pkwy. The warehouse store and design center will open with a team of about 50 full-time and part-time associates led by Tarsha Tillis, the store Chief Executive Merchant. "We're thrilled to announce our first store location in Augusta," said Tillis. "For more than two decades, Floor & Decor has had the opportunity to serve professionals and homeowners throughout the nation, and we are excited to expand our footprint in the Augusta market with this new location. We look forward to becoming part of the community and welcoming our newest neighbors into our store and making their renovation journeys easier, inspired, and more affordable."

16:06 EDT S&P Global upgrades Park-Ohio issuer credit rating to B from B- - Park-Ohio Holdings Corp announced that S&P Global has upgraded the ratings of Park-Ohio Industries, including the issuer credit rating to B from B-, and the issue-level rating on the company's $350M senior unsecured notes to B- from CCC+. S&P noted that the upgrades and stable outlook reflect improved operating performance in 2023, and their view that PKOH will continue to improve profitability, generate positive free operating cash flow and continue deleveraging over the next 12 months. ParkOhio is a diversified international company providing world-class customers with a supply chain management outsourcing service, capital equipment used on their production lines, and manufactured components used to assemble their products. Headquartered in Cleveland, Ohio, ParkOhio operates approximately 130 manufacturing sites and supply chain logistics facilities worldwide, through three reportable segments: Supply Technologies, Assembly Components and Engineered Products.

16:03 EDT Rallybio to partner with J&J on soultions to reduce risk of FNAIT - The company states: "Rallybio (RLYB) announced a collaboration with Johnson & Johnson (JNJ) to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia, or FNAIT. In addition, Rallybio received an equity investment of $6.6 million from Johnson & Johnson Innovation - JJDC, Inc. Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing2, thereby eliminating the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns. Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant individuals at higher risk of alloimmunization and FNAIT in the second half of 2024. Under this collaboration, Johnson & Johnson will provide funding for Rallybio to raise awareness of Johnson & Johnson's FNAIT clinical program in connection with Rallybio's ongoing FNAIT natural history study. Rallybio is also eligible to receive additional payments under the collaboration. RLYB212 is the only investigational therapy currently reported to be in clinical development to address the needs of pregnant individuals at risk of FNAIT who have not alloimmunized2. Johnson & Johnson is conducting a Phase 3 study of nipocalimab, an investigational monoclonal antibody targeting FcRn, in pregnant individuals who are already alloimmunized. As these individuals have the alloantibodies that can cause FNAIT, preventative treatment with RLYB212 would not be appropriate."

16:00 EDT Alpine Immune Sciences trading halted, news pending

14:15 EDT DocGo signs extension, starts transition of asylum seeker contract with NYC HPD - DocGo announced This extension is part of a planned transition that DocGo worked on in collaboration with NYC, demonstrating a continued partnership to ensure consistent and quality services for those in need. Under the extension, DocGo will continue to provide contracted services to assist with the ongoing asylum seeker crisis in upstate New York as needed through the end of 2024 and will provide accelerated transition assistance to a new provider of services for sites in New York City concurrent with the expiration of the original term of its HPD contract in May. DocGo will continue to provide its services to NYC through the extended term while prioritizing other growth initiatives across the Company's portfolio, including expansion of its programs with insurance partners, hospital systems, and population health programs. "We were pleased to step up and help New York City in its hour of need when other providers lacked the scale, resources, or rapid deployment expertise, and are confident in the quality and value we have delivered for this program," said Lee Bienstock, CEO of DocGo. "We are equally pleased to work with our partners at NYC to execute a coordinated transition over the rest of the year - it is part of our overall plan, and we shared our expectation that this program would moderate over the course of 2024 on our last earnings call. This transition will enable us to dedicate more of our corporate resources and energy towards pursuing growth opportunities across our key customer segments, and we are excited about the possibilities for expansion with our current customers and the new partnerships we are signing."

13:42 EDT Janux jumps 9% to $43.75 after Bloomberg report of takeover interest

13:34 EDT Imax and Miraj Cinemas announce partnership - IMAX and Miraj Cinemas announced a partnership, agreeing to install three new IMAX with Laser systems at locations across India. "This deal marks the first-ever collaboration between the two companies and IMAX's largest expansion in India in five years. Miraj Cinemas will add three new IMAX systems to key locations across India, including one in Mumbai - set to open in 2024 - one in Jaipur, and a third location to be determined at a later date," the companies stated.

12:41 EDT Alpine Immune trading resumes, shares up 14% after Bloomberg report - The stock is up $5.20 to $44.14 in midday trading.

12:36 EDT Alpine Immune jumps 7% to $41.74 after Bloomberg report of takeover interest

12:21 EDT Rent the Runway trading resumes

12:01 EDT Orgenesis, Germfree announce asset purchase and strategic partnership agreement - Germfree and Orgenesis announced an asset purchase and strategic partnership aimed at advancing Orgenesis' therapeutic programs and its suite of product development and GMP cell processing services. The collaboration's goal is to transform the production of cell and gene therapies, making these treatments more affordable and accessible to patients worldwide. Vered Caplan, CEO of Orgenesis, stated, "Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis' decentralized Octomera service platform, and its Octomera Mobile Processing Units and Labs globally. The partnership marks a significant milestone in the bio-manufacturing industry, as the industry begins to pivot to the paradigm-shifting distributed processing of cell and gene therapies. Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline with an emphasis on immuno-oncology. We are delighted to work with Germfree to meet the growing demand for our platform."

12:00 EDT Hexcel falls -12.2% - Hexcel is down -12.2%, or -$8.67 to $62.48.

12:00 EDT Cheetah Mobile rises 5.2% - Cheetah Mobile is up 5.2%, or 19c to $3.83.

11:40 EDT GCT Semiconductor Holding Inc trading resumes

11:04 EDT Caesars Sportsbook launches mobile wagering at Harrah's Gulf Coast - Caesars Entertainment announced that the Caesars Sportsbook Mississippi app is accepting mobile sports bets at Harrah's Gulf Coast in Biloxi, Mississippi. Sports fans 21 and older who are interested in wagering on sports via mobile devices can download the Caesars Sportsbook Mississippi app to register and deposit statewide but must be physically present on-property at Harrah's Gulf Coast to wager. The launch of the Caesars Sportsbook Mississippi mobile app complements the on-premise Caesars Sportsbook location, which accepted its first bets at Harrah's Gulf Coast in 2018.

10:35 EDT RTX's Pratt & Whitney announces $20M investment to increase GTF MRO capacity - Pratt & Whitney announced a $20M investment to increase the GTF maintenance, repair and overhaul capacity of its West Palm Beach Engine Center. The expansion will accommodate a 40% increase in capacity and is expected to be complete by the second half of 2025. Pratt & Whitney's West Palm Beach facility to increase GTF engine capacity by 40% through 2025. To accommodate the planned growth, the facility will increase its workforce by 25% over the next year and will add critical equipment in areas such as machining, test, clean and warehousing. It will also incorporate transformative technologies developed at the recently announced North American Technology Accelerator. West Palm Beach was transformed into a fully capable GTF MRO engine center in mid-2021. It was the first Pratt & Whitney facility to adopt an automated system that assembles the high-pressure compressor rotor and a refined overhead engine handling system. Since implementation, Pratt & Whitney has seen a more than 25% improvement in HPC rotor yield and a 50% reduction in process turnaround time. In 2023, Pratt & Whitney announced three GTF MRO facility expansions and five shop activations to support the growing GTF fleet. There are currently 16 active GTF MRO engine centers around the world, with another three expected to come online by 2025.

10:18 EDT Delta Air Lines: Q2 faces headwind from normalization of travel credits

10:16 EDT Delta CEO: 'This may be most constructive backdrop I've seen'

10:14 EDT Accenture acquires customer engagement agency Unlimited - Accenture announced it has acquired Unlimited, an integrated customer engagement agency, which will become part of Accenture Song. "The acquisition will enhance Accenture Song's ability to scale its offerings and unlock greater value from generative AI. With deep expertise in behavioral science, customer strategy and CRM activation, the acquisition of Unlimited further bolsters Accenture Song's capabilities to drive marketing transformation, relevance, and growth for its clients," the company stated. Terms of the transaction were not disclosed.

10:00 EDT Torrid rises 6.9% - Torrid is up 6.9%, or 30c to $4.67.

10:00 EDT Hexcel falls -10.1% - Hexcel is down -10.1%, or -$7.16 to $63.99.

09:47 EDT a.k.a. Brands rises 4.4% - a.k.a. Brands is up 4.4%, or 44c to $10.54.

09:47 EDT Torrid rises 6.9% - Torrid is up 6.9%, or 30c to $4.67.

09:47 EDT Aris Water Solutions falls -9.8% - Aris Water Solutions is down -9.8%, or -$1.48 to $13.67.

09:26 EDT U.S. Air Force Contract Augmentation Program awards Fluor $409M task order - Fluor announced that the U.S. Air Force Installation Contracting Agency awarded the company a task order contract for Pavement and Transportation Support North Field, Tinian, Commonwealth of the Northern Mariana Islands, CNMI. The task order was awarded under the Air Force Contract Augmentation Program V or AFCAP V. The cost-plus, fixed-fee task order has a 60-month period of performance and is valued at approximately $409M "We're honored to be selected to help strengthen the U.S. Air Force's deterrence capability as part of its global mission," said Tom D'Agostino, Group President of Fluor's Mission Solutions business. "Tinian airfield is located in a complex and ever-changing environment and is closely aligned with the nation's National Defense Strategy for the Indo-Pacific region. As we have proven, Fluor excels at delivering timely and cost-effective solutions in some of the most logistically challenged locations in the world."

09:23 EDT Ideal Power receives purchase order from power semiconductor, electronics leader - Ideal Power received a purchase order from a global leader in power semiconductor and power electronics solutions. The customer purchased B-TRAN devices and a circuit breaker evaluation board and is collaborating with Ideal Power on a solid-state circuit breaker design in connection with its launch of a multi-year DC power distribution system program.

09:14 EDT Hexcel down 11% at $63.40 in pre-market following BofA, Northcoast downgrades

09:12 EDT Qurate Retail Group promotes Bill Wafford to Chief Administrative Officer - Qurate Retail Group, part of Qurate Retail, announced that CFO Bill Wafford has been promoted to the expanded role of Chief Administrative Officer and CFO. In addition to his current role as CFO, Wafford will also oversee the company's Transformation office, which remains focused on embedding best practices to support the company's turnaround and growth, and the global People function, which includes compensation & benefits, payroll, talent acquisition, and people & organizational effectiveness. Wafford will continue to report to David L. Rawlinson II, President and CEO of Qurate Retail. The Transformation Office will continue to be led by Chief Transformation Officer, Bill Hunter, who will now report to Wafford. Linda Aiello, who was appointed as Chief People Officer in October 2022, previously made the decision to depart Qurate Retail Group for a new opportunity. She will stay with the company through April to support the transition. A formal search for a People leader to report to Bill Wafford has commenced. Wafford's appointment is effective immediately. Wafford joined the organization in March of 2023 as CFO. Prior to joining Qurate Retail, he held CFO positions with Everlane, Vitamin Shoppe, and JC Penney.

09:10 EDT Aptevo Therapeutics provides pipeline update - Aptevo Therapeutics announced advancements in both clinical programs and one preclinical program. A heavily pretreated breast cancer patient, enrolled in the ALG.APV-527 Phase 1 open-label, multi-center, multi-cohort trial for the treatment of multiple solid tumor types, entered the trial and improved from progressive disease to long-lasting stable disease while on therapy. The patient has remained on study for more than nine months and been successfully transitioned to a higher dose level, which may allow for increased clinical benefit. The trial is more than 50% enrolled and dosing in cohort five is imminent. The Company is on track to initiate part 1 of its upcoming two-part Phase 1b/2 trial in 1H 2024. The study will further evaluate APVO436 for the treatment of acute myeloid leukemia. Aptevo has partnered with premier CRO, Prometrika, for the upcoming study. The first part is a dose optimization trial evaluating standard of care venetoclax + azacitidine along with APVO436 as a frontline treatment for AML patients. It is planned as an open-label, multi-center, multi-cohort study. The trial will evaluate safety/tolerability and efficacy of the triplet combination at multiple dose levels. The therapeutic combination of venetoclax + azacitidine + APVO436 was selected based on outcomes from the Company's dose expansion trial that showed promising outcomes across all categories of evaluation including safety, efficacy, and duration of remission. APVO711 is currently progressing through preclinical evaluation intended to target a broad range of solid tumors. The Company continues to move this anticancer checkpoint inhibitor with added dual mechanism of action functionality toward the clinic. Key learnings to date include: APVO711 imparts beneficial attributes to both antigen presenting cells and T cells that boost the immune response targeted at controlling tumor cells; Experiments in cultured cells have confirmed that APVO711 enhances tumor cell killing by T cells; In vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors.

09:09 EDT Kingstone Companies appoints Manmohan Singh to board of directors - Kingstone Companies announced the appointment of Manmohan "Manu" Singh to its Board of Directors. Mr. Singh's appointment was in accordance with the terms outlined in an agreement between the Company and certain noteholders, pursuant to which the noteholders have the right to nominate one person to serve as a member of the Company's Board of Directors. Singh is the Group CFO and Head of Corporate Development for Angel Oak Companies, overseeing financial operations, including accounting and treasury, for all of Angel Oak's subsidiaries.

09:07 EDT Vita Coco launches Vita Coco Treats - Every now and then, we all deserve a little treat, and The Vita Coco Company (COCO) has just what you need. Its flagship coconut water brand, Vita Coco, is introducing Vita Coco Treats, a new coconutmilk beverage crafted for those moments when you're in the mood for something light, sweet, and satisfying. Combining the flavors of creamy coconut and sweet strawberries, Vita Coco Treats offers a refreshingly delicious drink that can make anyone's day a little brighter. Guaranteed to add fun to your Target run, Vita Coco Treats launches exclusively at Target (TGT) stores in the beverage aisle nationwide on April 10 for the suggested retail price of $3.49 per 16.9-oz container. Vita Coco Treats will be available for purchase at select Costco (COST) locations and on Amazon (AMZN) later this spring.

09:04 EDT Kyndryl Holdings and Ernst & Young renew agreement - Kyndryl announces the renewal of a five-year agreement, with Ernst & Young to continue managing its SAP environment, as well as provide modernization and security services for the mission-critical systems that support its auditing and consulting operations. This work builds on a nearly decade-long collaboration under which Kyndryl has run and managed EY SAP workloads. EY will also leverage the experience of Kyndryl Consult to help analyze and optimize its SAP processes. With insight and guidance from Kyndryl Consult experts, EY can identify new performance efficiencies that support its current SAP environment, as well as its longer-term growth and modernization goals. Additionally, Kyndryl Consult will enhance the cyber resiliency of EY IT operations with further security for mission-critical workloads, deliver service continuity and evolve data protection around business transactions with EY customers.

09:03 EDT DT Cloud Acquisition announces upcoming automatic unit separation - DT Cloud Acquisition Corporation announced that, commencing Friday, April 12, 2024, holders of the units sold in the Company's initial public offering of 6,900,000 units may commence separate trading of the underlying component securities. Each Unit consists of one ordinary share, par value $0.0001 per share, and one right to receive one-seventh of one Share (upon the consummation of the Company's initial business combination. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol "DYCQU." The Shares and Rights that are separated will trade on Nasdaq under the symbols "DYCQ" and "DYCQR," respectively. Holders of the Units will need to have their securities brokers contact Continental Stock Transfer & Trust Company at 1 State Street 30th Floor, New York, NY 10004-1561, the Company's transfer agent, in order to separate the Units into Shares and Rights. The Units were initially offered by the Company in an underwritten offering through Brookline Capital Markets, a division of Arcadia Securities, LLC, which acted as the sole book runner for the offering and as the representative of the underwriters in the offering.

09:02 EDT GreenPower Motor plans to deliver additional 88 all-electric school buses - GreenPower Motor Company announced that it plans to deliver an additional 88 all-electric Type D BEAST and Type A Nano BEAST school buses to school districts in West Virginia in GreenPower's fiscal year 2025 which began April 1. In January 2024, the EPA announced an $18,565,000 grant awarded to GreenPower of WV for the deployment of GreenPower's all-electric, purpose-built, zero-emission school buses in seven West Virginia counties. The grant includes funding for the charging infrastructure to ensure a proper charging strategy for the deployment. Once delivery is complete, nearly 100 GreenPower all-electric school buses will be in operation in West Virginia. The announcement of the planned deliveries comes on the heels of a record number of all-electric, purpose-built, zero-emission school bus deliveries during GreenPower's just ended 2024 fiscal year.

09:01 EDT Sealsq announces strategic developments, provides updates on progress - SEALSQ unveiled a series of comprehensive strategic initiatives and progress reports during its Investor Day at Nasdaq MarketSite on April 1, 2024. These initiatives underscore the Company's commitment to technological advancement and maintaining its position as an industry leader in the era of quantum computing. The event was highlighted by an in-depth presentation delivered by CEO Carlos Moreira, and CFO John O'Hara. The presentation covered an array of topics, including current market trends, strategic initiatives, and investment highlights, and was concluded with a Q&A session that provided further insights into the Company's trajectory.

08:47 EDT PodcastOne launches 'Ransom: Position of Trust' podcast - PodcastOne has acquired the exclusive sales and distribution rights to the top true crime podcast producer, KSL Podcasts new podcast, Ransom: Position of Trust which will debut May 15, 2024 wherever podcasts are heard. KSL Podcasts is the producer behind hit top true crime podcasts COLD and The Letter.

08:42 EDT Avicanna completes topical gel observational real-world evidence study - Avicanna announced the completion of its observational real-world evidence study using RHO Phyto branded cannabigerol transdermal gel on patients with musculoskeletal pain and inflammation. The RWE study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% cannabidiol and 1% CBG on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain. Seventy-one participants completed baseline testing and a follow up at one month including demographic, medical history, medication use and two standardized symptom questionnaires. The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores as compared from baseline to one month. Specifically, there was a reported 35.4% improvement in health-related domains including symptoms, physical functioning, daily activities and work, physical well-being, and confidence to manage symptoms. In addition, evaluation of the Edmonton Symptom Assessment System questionnaire also revealed an improvement in pain, sleep, anxiety, and well-being symptoms from baseline to one month. The RWE study participants with an average age of 58 +/- 15 all presented with symptoms of chronic pain. According to ICD-10 diagnosis classification, 21.1% of participants had a diagnosis related to arthritis, 17.5% of participants with a diagnosis of dorsalgia, 12.3% with fibromyalgia, and 8% with chronic intractable pain. Prior to initiation of the study, study participants reported they were taking an average of ten medications including NSAIDs, opioids, antidepressants, or skeletal muscle relaxants. Each RWE study participant was assigned a common treatment plan of a combination of a CBD oil or balance oil with the RHO Phyto CBG Transdermal Gel.

08:41 EDT Brightcove appoints John Wagner as CFO - Brightcove announced John Wagner is joining the company as the CFO, effective immediately. Wagner will be responsible for Brightcove's global financial organization, which includes financial operations, planning, accounting, and investor relations. Wagner brings more than two decades of strategic and operational financial leadership experience within the technology industry. He brings extensive experience managing and scaling financial operations to support growth and profitability in addition to public and private capital raising and acquisitions. Most recently, Wagner served for nine years as the CFO of EverQuote, an online insurance marketplace, where he oversaw the company's successful initial public offering and led the finance organization for five years post-IPO.

08:40 EDT Sidus to host HEO's NEI imager aboard upcoming Lizzie-Sat launch - Sidus Space announced at the Space Symposium in Colorado Springs that it has finalized an additional agreement with HEO, a provider of non-Earth imaging or NEI and data, for NEI payload and data services. Under the agreement, Sidus Space will host HEO's NEI imager, HOLMES-006, onboard LizzieSat-3, as part of the Bandwagon-2 launch scheduled for November 2024, along with a monthly data services contract. This marks the second agreement between HEO and Sidus Space, as Sidus Space's LizzieSat-2 will be hosting HEO's HOLMES-004 on the same launch. HEO's Holmes Imager is a telescopic space camera designed and developed to be hosted as a secondary payload on spacecraft. Holmes is the world's first commercial camera dedicated to NEI, which captures images of resident space objects. The images obtained can provide valuable information about the identification, physical characteristics, movements, and interactions of satellites in orbit. Sidus's LizzieSats will take HEO's NEI sensors to mid-inclination low-Earth orbit for the first time, increasing orbit diversity and enabling higher-quality images and data on a range of new and previously covered space objects. "We are accelerating our work to proliferate NEI sensors in orbit, and we love partnering with companies at the cutting edge of spacecraft deployment," said Dr Will Crowe, CEO and Co-Founder of HEO. "We've loved working with Sidus and are excited about their plans." "We are honored to have earned HEO's trust and confidence in our ability to provide the platform for their NEI and data collection," said Carol Craig, CEO of Sidus. "Our companies work well together, and we look forward to a strong partnership to further enhance and expand the space ecosystem by offering a variety of valuable imagery and data."

08:39 EDT KULR Technology delivers customized battery solution for U.S. Army - KULR Technology Group announces the successful delivery of its custom-designed KULR ONE battery packs to the United States Army, a crucial step in bolstering the longevity and efficiency of Uninterruptible Power Supplies in tactical command settings. Under a multi-year contract, KULR has achieved a significant milestone by tailoring its KULR ONE battery pack specifically for the Army's effort to modernize future command posts. Michael Mo, CEO of KULR, expressed his pride in the project's success: "Delivering these customized battery packs to the United States Army represents a significant achievement for KULR. It underscores our commitment to developing specialized solutions that meet the exacting needs of our clients, particularly in critical, high-stakes environments. The KULR ONE pack exemplifies our dedication to innovation, safety, and performance in energy management."

08:38 EDT Macy's announces termination of Arkhouse proxy contest, adds two board nominees - Macy's announced the appointment of two new independent directors, Richard Clark and Richard Markee, to its board of directors, effective immediately. The appointments of Clark and Markee follow the board's engagement with Arkhouse Management, resulting in the withdrawal of its director nominations. The company is also implementing previously announced changes to its board, effective immediately. Tony Spring, chief executive officer and chairman-elect of Macy's, has assumed the chairman role. In addition, Douglas Sesler, whose nomination to stand for election to the board at the 2024 annual meeting of shareholders was announced on March 14 has been appointed as an independent director. These changes follow the planned retirements of Jeff Gennette and Frank Blake from the Macy's board. In connection with the Clark and Markee appointments, the Company has entered into an agreement with Arkhouse and its affiliates that provides for the withdrawal of Arkhouse's director nominations, among other customary provisions. Clark and Markee will join the board's finance committee, which in addition to its existing responsibilities, will oversee the evaluation of and make recommendations to the full board regarding the acquisition proposal submitted by Arkhouse and Brigade Capital Management. The agreement between the company and Arkhouse will be filed on a Form 8-K with the Securities and Exchange Commission. Following today's Board appointments and retirements, the Macy's, Inc. Board comprises 15 directors, 14 of whom are independent.

08:37 EDT Nexalin Technology issues letter to shareholders - Nexalin Technology provided the following letter to shareholders from the Company's CEO, Mark White, including updates regarding the growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as, progress on its new Gen-3 HALO Clarity & Virtual Clinic model:"We've hit the ground running in 2024 with a series of favorable developments that solidify Nexalin's position as an innovator in the field. We recently announced positive results from a clinical study conducted at the University of California, San Diego... We also announced encouraging results from a recent clinical study of our Gen-2 tACS device for treating adult patients with chronic insomnia... Additionally, the Nexalin clinical teams have published 6 additional clinical studies in recognized international peer-reviewed journals evaluating the safety, tolerability and efficacy of the new advanced 15 milliamp waveform.. Building on our strong clinical momentum, we recently unveiled the HALO Clarity, a headset powered by various processing systems and microprocessors to deliver a new Gen-3 waveform at 15 milliamps... Our Virtual Clinic will allow patients to be treated by the HALO within the privacy of their own homes... The development of the Virtual Clinic is far along and is expected to support the monitoring and collection of HALO use data by medical professionals in a seamless manner resulting in an integrated workflow - from assessment, to authorization, to shipment - all under medical supervision... On the international front, we announced regulatory approval in Oman, and commenced sales of our Gen-2 Neurostimulation Device to a new Mental Health Center in Oman dedicated to our technology... We look forward to securing approval in other countries, with the ultimate goal of gaining FDA clearance in the United States... Nexalin continues to innovate and enhance our IP portfolio... The global mental health crisis continues to be a pressing concern. Nexalin remains steadfast in our commitment to developing safe and effective treatments that could be used to alleviate the burden of anxiety, insomnia, depression and other mental health conditions...Overall, we believe our neurostimulation device has the potential to transform the standard of care for the treatment of mental health disorders, a massive global market estimated to be $383 billion in 2020 and projected to reach $537 billion by 2030. "

08:36 EDT Metals Company appoints Steve Jurvetson as vice chairman, special advisor to CEO - TMC the metals company announced the appointment of Steve Jurvetson to its Board of Directors as Vice Chairman and engagement as a Special Advisor to the CEO. As Co-founder and Managing Director of Draper Fisher Jurvetson, he led the VC firm's founding investments in several companies that had successful IPOs and others that were acquired, representing $800 billion of aggregate value creation. In 2018, Mr. Jurvetson co-founded Future Ventures to focus on trailblazing, purpose-driven entrepreneurs with unique ideas that have the potential to reinvent entire industries-from nuclear fusion and space exploration to sustainable energy and AI.

08:35 EDT Bid4Assets to host online tax-defaulted property sale for Riverside County - The Riverside County, California Treasurer-Tax Collector's Office will host its annual tax-defaulted property sale in collaboration with online auction provider Bid4Assets, the leading online marketplace for the sale of distressed government real estate. Online bidding for more than 152 properties will begin April 25, 2024, at 8:00 AM PT and end April 30, 2024, at staggered times. The sale includes a wide range of properties, with minimum bids as low as $2,575 for a .18-acre lot in Blythe to a minimum bid of $236,027 for a 2.16-acre parcel with a commercial structure assessed at over $500,000. All auctions are no reserve, meaning the highest bid at or above the minimum will win the property. Bidders must register for a free Bid4Assets account and fund a $2,500 deposit plus a $35 processing fee before being eligible to participate in the sale.

08:33 EDT SRM announces Sip with Me cups available at Landry's Rainforest Cafe - SRM Entertainment announced that SRM's patented Sip With Me cups are now available at Landry's Rainforest Cafe located at Disney's Animal Kingdom as well as Disney Springs. They can also be found at other Rainforest locations including Galveston Island, TX, San Antonio Riverwalk, Opry Mills in Nashville, TN and The Mall of America. Additionally, they will soon be featured online at https://shop.landrysinc.com/collections/rainforest-cafe. Landry's, Inc., is a multi-brand dining, hospitality, entertainment, and gaming corporation headquartered in Houston, Texas. Landry's, Inc. owns and operates more than 600 restaurants, hotels, casinos, and entertainment destinations in 35 U.S. states and the District of Columbia.

08:32 EDT T. Rowe Price reports preliminary AUM $1.54T at March 31 - T. Rowe Price Group reported preliminary month-end assets under management of $1.54T as of March 31. Preliminary net outflows were $1.2B for March and $8B for the quarter-ended March 2024.

08:22 EDT AIM ImmunoTech announces interim report data from Ampligen study - AIM ImmunoTech announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease. Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver. Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors. In the ongoing, investigator-initiated Phase 2, single-arm efficacy/safety trial, University of Pittsburgh Medical Center researchers saw an Objective Response Rate of 45% when combining Ampligen, pembrolizumab and cisplatin in platinum-sensitive subjects with recurrent ovarian cancer. ORR includes complete response and partial response to treatment. There was a total Clinical Benefit Rate of 55% when including patients who experienced stable disease. Researchers also reported a median Progression-Free Survival of 7.8 months. Robert Edwards, MD, Chair of the Department of Obstetrics, Gynecology & Reproductive Sciences and Co-Director of Gynecologic Oncology Research at Magee-Womens Hospital of UPMC, stated: "These results are incredibly favorable when compared to data from the hallmark Phase 2 study Keynote-100, which looked at the use of pembrolizumab alone in the treatment of recurrent ovarian cancer in both platinum-resistant and platinum-sensitive subjects. Keynote-100 reported an ORR of approximately 8% in these subjects - meaning that the new data analysis showed that combining pembrolizumab treatment with Ampligen created a greater than 500% increase in ORR over the Keynote-100 findings. Additionally, Keynote-100's median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study. Additionally, the new ovarian cancer data analysis revealed an acute increase in anti-tumor immunity - specifically in biomarkers CXCL9, CXCL10, CXCL11 - which is consistent with the immune-stimulatory effects of Ampligen that researchers have seen in clinical studies of other solid tumors, including triple-negative breast cancer, pancreatic cancer and colorectal cancer. We look forward to publishing a more detailed analysis of these data in a peer-reviewed clinical journal this summer."

08:16 EDT Palisade Bio presents development overview of PALI-2108 - Palisade Bio presented at IBD Innovate: Product Development for Crohn's & Colitis held April 9-10, 2024 in Cambridge, MA. As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company's research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled, "Advancing PALI-2108: Discovery to Strategy Positioning," which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development. "We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year," commented Dr. Jones. As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn's and Colitis Foundation, through its IBD Ventures program.

08:14 EDT Silo Pharma exercises option to license SPC-14 from Columbia University - Silo Pharma has exercised its option to license Alzheimer's disease therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024. Silo believes that SPC-14 should be eligible for development under the FDA's 505(b)(2) regulatory pathway.

08:12 EDT Cumulus Media announces extension of expiration time in exchange offer - Cumulus Media subsidiary, Cumulus Media New Holdings, has further extended the Expiration Time in its previously-announced Exchange Offer and Consent Solicitation, in which the Issuer offered to exchange any and all of the Issuer's outstanding 6.750% Senior Secured First-Lien Notes due 2026 for new 8.750% Senior Secured First-Lien Notes due 2029, to be issued by the Issuer, upon the terms of and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated February 27, 2024. The Issuer is further extending the previously announced Further Expiration Time, which was 5:00 p.m., New York City Time, on April 9, 2024, to 5:00 p.m., New York City Time, on April 12, 2024. The deadline to validly withdraw tenders of the Old Notes was not extended and expired at 5:00 p.m., New York City Time, on March 11, 2024. The Exchange Offer and Consent Solicitation will expire at the New Further Extended Expiration Time, unless extended or terminated. The New Further Extended Expiration Time is subject to earlier termination, withdrawal or extension by the Issuer in its sole and absolute discretion. All other terms of the tender offer remain unchanged. The previously announced Early Tender Time lapsed at 5:00 p.m., New York City Time, on March 18, 2024. As such, holders that validly tender and do not validly withdraw their Old Notes prior to the New Further Extended Expiration Time are only eligible to receive $770.00 principal amount of New Notes. The Issuer will pay accrued and unpaid interest to, but excluding, the Settlement Date, which is as soon as practicable after the New Further Extended Expiration Time, in cash, to holders of Old Notes accepted for exchange pursuant to the Exchange Offer and Consent Solicitation. As of 5:00 p.m., New York City time, on April 9, 2024, approximately $15 million aggregate principal amount of the Old Notes had been validly tendered pursuant to the Exchange Offer and Consent Solicitation and not withdrawn.

08:11 EDT BriaCell reports preclinical data at 2024 AACR meeting - BriaCell Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-OTS+ and Bria-PROS+, in a poster session during the 2024 American Association for Cancer Research, AACR, Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA. "Our data demonstrates enhancement of immune responses and expanded mechanisms of action of the Bria-OTS platform," commented Miguel Lopez-Lago, PhD, BriaCell's Chief Scientific Officer. "We anticipate that our novel immunotherapeutic platform will provide potent and long-lasting anti-cancer activity in cancer patients. We view our technology as a significant scientific advancement in the field of oncology and personalized immunotherapy."

08:09 EDT Gorilla Technology, Thames Freeport announce strategic alliance - Gorilla Technology announced they have signed a Memorandum of Understanding with Thames Freeport, a pivotal hub for trade and logistics in the United Kingdom. This strategic alliance is set to revolutionise the Thames Freeport area, aligning an ambitious Smart City Strategy programme and leveraging the Thames Freeport Investment Fund to drive innovation and sustainable growth. Under this partnership, Gorilla Technology will spearhead the development of advanced technological frameworks within Thames Freeport's infrastructure, focusing on enhancing efficiency, security and sustainability. This collaboration marks a significant milestone in Thames Freeport's journey towards becoming a fully integrated smart city, setting new standards for the industry and represents a significant leap towards redefining its key industry sectors by setting benchmarks for efficiency, security and sustainable development.

08:08 EDT LOBO EV to showcase solar-powered EVs at Canton Fair - LOBO EV Technologies announced its subsidiary, Tianjin Bibosch Intelligent Technology Co., Ltd., will participate in the 135th China Import and Export Fair, slated to take place on Pazhou Island, Guangzhou, China, from April 15 to April 19, 2024. LOBO will introduce its latest advancements in electric mobility at the Canton Fair, with a spotlight on its newly developed solar energy series. This includes a range of solar-powered e-trikes, golf carts, and ATV/UVT models, all designed to address the critical challenges of charging convenience and travel range. The Canton Fair will also serve as the launch pad for LOBO's new delivery e-bike series, designed to address the burgeoning demand in the food and goods delivery sector which is being fueled by the growth of services from leading fast-food restaurants and major retailers. China's parcel delivery industry delivered a record 110.6 billion packages in 2022, according to data from Cushman & Wakefield, a leading global services firm.

08:06 EDT Qualigen Therapeutics announces presentation on Pan-RAS Inhibitors - Qualigen Therapeutics announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research Annual Meeting 2024 held April 5 - 10 in San Diego, California. "We continue to see cancers developing resistance to current clinical agents that target a particular K-RAS mutation, and we remain optimistic that a more broad-based Pan-RAS inhibitor may help resolve these issues", commented Michael Poirier, Qualigen's Chairman and CEO. "The data show that our Pan-RAS inhibitors can interfere with K-RAS, H-RAS and N-RAS activity and signaling, on both mutant and wild type RAS. This suggests there could be a viable window for Pan-RAS inhibitors in patients with RAS driven tumors, as well as a potentially broader application to cancers not usually associated with RAS, such as certain classes of Ovarian, Breast, and NF1 loss driven Malignant Peripheral Nerve Sheath Tumors." Abstract #3320 - "Novel Direct Pan-RAS Inhibitors" - Howard Donninger, Rachel Ferril, Becca von Baby, Joe Burlison, Mike Sabo, Tariq Arshad, Rob Monsen, John Trent, and Geoffrey J. Clark - Results demonstrated the compounds' role as Pan-RAS inhibitors. These compounds effectively target and disrupt the activity and signaling of various RAS mutations, including K-RAS, H-RAS, and N-RAS, impacting both mutant and wild type variants. Encouragingly, in vivo studies indicate minimal toxicity associated with these compounds, likely due to their selective suppression of RAS signaling at the administered doses. These results hint at a promising therapeutic potential for Pan-RAS inhibitors in clinical settings, emphasizing their significance in cancer treatment strategies.

08:05 EDT Fluent announces 1-for-6 reverse stock split - Fluent announced that it will effect a 1-for-6 reverse split of the issued shares of its common stock, effective at 6:00 p.m. Eastern Time on April 11, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Friday, April 12, 2024. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "FLNT" with the new CUSIP number 34380C 201. Fluent is implementing the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

08:04 EDT Arcutis Biotherapeutics appoints David Topper as CFO - Arcutis Biotherapeutics announced that David Topper has been appointed CFO effective April 10, 2024. He is replacing John Smither, who rejoined Arcutis as interim CFO in August 2023. Mr. Smither will remain at Arcutis through the end of April to ensure a smooth transition. Mr. Topper joins Arcutis from Inmagene Biopharmaceuticals, a global clinical stage pharmaceutical company, where he served as CFO.

08:03 EDT Skye Bioscience uplists to Nasdaq Global Market - Skye Bioscience announced that the Company has received approval to list its common stock on the Nasdaq Global Market stock exchange. The Company's common stock is expected to commence trading on Nasdaq at the market open on Thursday, April 11th, 2024, under the ticker symbol "SKYE". The Company's common stock will no longer trade on the over-the-counter securities market.

08:02 EDT Sunrun prices $230M senior securitization of solar, battery systems - Sunrun has priced a securitization of leases and power purchase agreements. The securitized leases and power purchase agreements have been in service for an average of 6.75 years, and thus the vast majority of the portfolio is after the 'flip point' in tax equity structures. The securitization was issued with a single class of notes that are A rated by Kroll with a principal amount of $230 million, a weighted average life of 7 years and final maturity of February 1, 2055. As the portfolio has a remaining contractual life of 13.25 years and the vast majority of the portfolio has already reached the tax equity fund 'flip point', the structure was issued without an Anticipated Repayment Date and instead fully amortizes over the contractual life at a fixed interest rate. The initial balance of the notes represents an approximate 85% advance rate on Securitization Share of ADSAB. The advance rate is 7 percentage points higher than the senior tranche in Sunrun's prior securitization of more recently originated assets. The notes were priced at a 6.27% coupon and represented a 6.328% yield. The coupon rate reflects a spread of 195 basis points over the benchmark swap rate at the time. The notes are backed by a diversified portfolio of 27,094 solar rooftop systems distributed across 19 states and Washington D.C. and 65 utility service territories. The weighted average customer FICO score is 739. The transaction is expected to close by April 17, 2024. The portfolio is jointly owned by National Grid and Sunrun, with NG receiving the majority of cash flows through 2042. Bank of America was the sole structuring agent and served as joint bookrunner along with Truist and KeyBanc.

07:48 EDT Blackwells files proxy statement for Braemar Hotels & Resorts annual meeting - Blackwells Capital, a shareholder of Braemar Hotels & Resorts, has filed a definitive proxy statement with the Securities and Exchange Commission in connection with its nomination of four candidates - Jennifer Hill, Betsy McCoy, Steven Pully and Michael Cricenti - for election to the board of directors of Braemar at the company's 2024 annual meeting of shareholders to be held on May 15. Jason Aintabi, Chief Investment Officer of Blackwells, said: "Braemar is in a pitiful state. Despite its exceptional assets, Monty Bennett's failed leadership has had shareholders suffer through an almost 90% decline in share price over the last 10 years.i During the same period, management fees paid to Ashford Hospitality Advisors, LLC, have grown by over 575%. Braemar has become a thinly traded microcap stock with a measly $133 million market capitalization. Astonishingly, the termination fee Mr. Bennett and Ashford think they are owed-after having presided over this disaster-outstrips the entire market value of Braemar. If this is not corporate piracy, we simply do not know what is... Bennett can commission childish articles about Blackwells and its principals, he can continue to drive shareholders away from the real issues, and file meritless litigation meant to preserve his gravy train. This will not change the fact that Mr. Bennett must be removed from his roles at Braemar, and the external management agreement that Blackwells believes turns the Company into his personal "piggybank" must be terminated. Braemar's current directors have cowered to poor governance practices, and have permitted the Company's management to entrench themselves at the expense of shareholder value. The Blackwells Nominees possess the skills necessary to transform the Board and business of Braemar, unlocking value for shareholders that the Board has incessantly decimated over the past decade."

07:39 EDT FirstService's First Onsite has recently acquired All Restoration Solutions - FirstService announced that its subsidiary, First Onsite Property Restoration, has recently acquired All Restoration Solutions. The executive leaders of ARS will continue to hold a minority equity stake and oversee day-to-day operations. Terms of the transaction were not disclosed. "This acquisition is highly complementary to our existing presence in the Southeast U.S.," said Jeff Johnson, Chief Executive Officer of First Onsite. "ARS brings a strong leadership team and reputation for service excellence, while adding a blue-chip client base in attractive market sectors. We welcome the ARS team and look forward to collectively driving growth in this high-priority region," he concluded.

07:38 EDT Marimed partners with Boston music venues - MariMed announced a historic marketing partnership with two iconic venues in Boston, the MGM Music Hall Fenway and Citizens House of Blues Boston. This groundbreaking partnership marks Nature's Heritage as the Exclusive Cannabis Sponsor, elevating the brand at highly anticipated shows to connect with millions of passionate music fans throughout the year. With an onsite fan experience, prime real estate on venue video screens and digital ad space, Nature's Heritage becomes part of unforgettable live music events at MGM Music Hall Fenway and Citizens House of Blues Boston.

07:36 EDT Dragonfly Energy announces results from Cost & Sustainability Assessment - Dragonfly Energy Holdings announced the results from a Cost & Sustainability Assessment conducted by Sphere Energy, a global battery testing and advisory firm. The assessment highlights significant cost and sustainability improvements made by Dragonfly Energy's patented dry electrode battery manufacturing process when compared to the state-of-the-art (slurry cast) production process currently employed by conventional battery cell manufacturers. Results and findings presented within the assessment were based on specific data from Dragonfly Energy's cell manufacturing pilot line located in Northern Nevada whilst covering a global supply chain. "The findings from the Sphere Energy Cost & Sustainability Assessment support expectations that our innovative dry electrode process results in significant energy and cost efficiencies while promoting environmental sustainability," Dr. Denis Phares, Chief Executive Officer of Dragonfly Energy, said. "Through extensive research and development, we believe Dragonfly Energy is positioned to deliver a transformative cell manufacturing technology, which has the potential to fundamentally reshape the lithium-ion battery industry's approach to viable energy storage solutions. We believe this focus on domestic innovation is paramount for the US to achieve self-sufficiency in battery production."

07:31 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio announced that on April 5, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

07:20 EDT Clearmind files U.S. patent application for psychedelic-based treatment - Clearmind Medicine has filed a patent application with United States Patent and Trademark Office for the use of 3-methylmethcathinone, to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.

07:16 EDT Hookipa Pharma receives PRIME designation for HB-200 program - HOOKIPA Pharma announced that members of HOOKIPA's Executive Team will host an investor call summarizing the Company's constructive regulatory interactions with the U.S. Food & Drug Administration and the European Medicines Agency. HOOKIPA and the FDA have aligned on the design and protocol of the Company's upcoming pivotal Phase 2/3 clinical trial of HB-200 in combination with pembrolizumab. The investor call will be held on April 25, 2024, at 8:00 a.m. ET. The Company also announced that EMA has granted PRIME designation for the investigational product HB-200 in combination with pembrolizumab for the treatment of patients with Human Papillomavirus 16-positive recurrent/metastatic PD-L1 CPS greater than or equal to 20 oropharyngeal squamous cell carcinoma in the first line setting. PRIME designation is intended to expedite development and review of drug candidates, alone or in combination with other drugs. Eligibility and approval are based on preliminary clinical evidence and indicate that the drug candidate may offer substantial improvement over existing therapies.

07:13 EDT Colliers International announces acquisition of affiliate - Colliers announced the acquisition of its affiliate, Colliers Philadelphia. Now as a company-owned operation, Colliers Philadelphia will continue to build on its market leadership by leveraging the full resources of Colliers' enterprising and fast-growing platform and increasing its service capabilities. "Our acquisition of Colliers Philadelphia is consistent with our strategy of acquiring and growing significant affiliate operations that have become top players in their respective markets," said Gil Borok, President and Chief Executive Officer Colliers U.S. & LATAM. "Philadelphia is the eighth largest metropolitan area in the U.S. and home to many Fortune 1000 companies. As a vibrant and influential market, our ownership will allow us to better service the requirements of our clients locally, nationally, and internationally."

07:12 EDT PyroGenesis, Constellium sign LOI for plasma remelting furnaces - PyroGenesis Canada (PYR) has signed a collaboration agreement with Constellium (CSTM) to develop plasma torches and associated processes as suitable heating sources for aluminum remelting furnaces. This announcement is further to the Company's press releases dated April 20, 2022, and March 31, 2023, which provided updates on its aluminum business offerings, and after the recent successful completion of an initial joint evaluation of plasma technology in aluminum melting test furnaces. PyroGenesis and Constellium have agreed to implement an industrial scale aluminum remelting furnace, which would serve Constellium's decarbonization strategy. The project would consist of two phases: conducting feasibility studies and engineering; and implementing a demonstrator plasma-heated furnace system in one of Constellium's aluminum casthouses.

07:10 EDT Ocugen announces CHMP of EMA reviewed Phase 3 study design for OCU400 - Ocugen announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, reviewed the study design, endpoints and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa and provided acceptability of the U.S.-based trial for submission of a Marketing Authorization Application. EMA provided this opinion based on safety and tolerability of OCU400 demonstrated in the Phase 1/2 study. The Phase 3 liMeliGhT study will have a sample size of 150 participants primarily in the U.S.-one arm of 75 participants with RHO gene mutations and the other arm with 75 participants that are gene agnostic. In each arm, participants will be randomized 2:1 to the treatment group and untreated control group, respectively. The positive scientific advice from EMA is in alignment with U.S. FDA clearance of the IND amendment to initiate the Phase 3 liMeliGhT clinical trial of OCU400. OCU400 is the first gene therapy to enter Phase 3 with a broad RP indication. Previously, OCU400 received broad Orphan Drug Designation for RP and Leber congenital amaurosis in the EU.

07:08 EDT Compugen announces publication of peer reviewed paper on IL-18 - Compugen announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research annual meeting on April 5-11 in San Diego, California. "There is a growing recognition of the importance of the IL-18 pathway in cancer immunology reflected in the surge in investment and collaboration in this space," said Anat Cohen-Dayag, President, and CEO of Compugen. "Through our computational discovery work at Compugen we identified that IL-18 binding protein, a natural inhibitor of IL-18, is highly expressed in patients as a potential immune resistant mechanism. Taking advantage of the high levels of endogenous IL-18BP bound-IL-18 in the tumor microenvironment, we, along with our partner Gilead Sciences are developing COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics."

07:06 EDT Xtract One partners with Oak View Group to secure Co-op Live - Xtract One Technologies is partnering with Oak View Group to bring its fan screening solution to secure all entrances of Co-op Live in Manchester, England opening on April 23, 2024. The next generation, 23,500 capacity venue is the largest arena in the UK and is Xtract One's first OVG customer partnership in Europe. In this three-year contract, Xtract One's SmartGateways will provide this new venue with fast and frictionless fan screening that optimizes their experience without compromising security, with an AI-powered, multi-layered security solution that secures all patrons.

07:05 EDT Interactive Strength to exhibit CLMBR at FIBO Global Fitness - Interactive Strength announced that the Company's CLMBR brand will be exhibited at FIBO Global Fitness, the world's largest trade show for fitness, wellness and health in Cologne, Germany on April 11-14. FIBO is the annual main event where global leaders across the health and fitness industry gather to discover the latest equipment, products and services. This is the first year where the commercial version of CLMBR is available at FIBO Global Fitness. As a result of TRNR acquiring CLMBR and entering a Worldwide Exclusive Distribution Agreement with WOODWAY earlier this year, CLMBR is now available worldwide for commercial customers.

07:04 EDT Ginkgo Bioworks and Novo Nordisk expand strategic partnership - Ginkgo Bioworks announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years. Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medications. The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio.

07:03 EDT EZGO Technologies announces one-for-forty reverse shares split - EZGO Technologies announced that on March 22 its board of directors approved a reverse split of its ordinary shares on a one-for-forty basis. The Company's ordinary shares will begin trading on a post-split basis on April 12. As a result of the Reverse Share Split, each forty pre-split ordinary shares of the Company will be automatically combined into one ordinary share without any action on the part of the holders, with par value of the ordinary shares of the Company being changed from 0.1c per share to 4c per share, and the Company's issued and outstanding ordinary shares will be reduced from 102,165,549 to approximately 2,554,139. The Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EZGO" under a new CUSIP number - G5279F110. The Reverse Share Split is intended to increase the market price per share of the Company's ordinary shares to allow the Company to maintain its Nasdaq listing. The Reverse Share Split will not be submitted to a vote of the Company's shareholders as a vote was not required under the laws of the British Virgin Islands. The Company's transfer agent, VStock Transfer, will act as the exchange agent. Adjustments made to ordinary shares represented by physical stock certificates can be made upon surrender of the certificate to the transfer agent.

07:02 EDT MoonLake Immunotherapeutics enters three-year partnership with Komodo Health - MoonLake Immunotherapeutics and Komodo Health announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake's nanobody-based therapy in hidradenitis suppurativa and active psoriatic arthritis, two underdiagnosed diseases with significant unmet patient needs. Through this multiyear technology partnership, MoonLake will utilize Komodo's Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams. Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: "We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors. Komodo's data-driven intelligence is expected to be a critical tool as we work towards commercialization and delivering transformative therapies to patients."

06:46 EDT Lazard reports preliminary AUM $250.4B as of March 31 - Lazard reported that its preliminary assets under management as of March 31 totaled approximately $250.4B. The month's AUM included market appreciation of $5.3B, net outflows of $2.5B and foreign exchange depreciation of $0.4B. Preliminary average AUM for the quarter ended March 31 was $247B.

06:33 EDT Oculis names Dr. Snehal Shah as President of Research & Development - Oculis Holding announced the appointment of Dr. Snehal Shah, executive leader with over two decades of research & development and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and development strategies, and working towards achieving market authorizations by directing global regulatory activities required for future New Drug Application submissions to the U.S. FDA, and the equivalent for regulators in other territories.

06:27 EDT American Water says it is prepared to meet final EPA's drinking water standards - American Water confirmed that it is prepared to meet the final U.S. Environmental Protection Agency's, or EPA, national drinking water standards for PFAS, which were issued just today. "While we are assessing any changes from the proposed rule to the final rule, we have been preparing for full compliance, from capital planning to engineering to water quality. We have already gained significant experience from complying with individual state PFAS requirements and have been doing so for quite some time. We strongly support these efforts to protect public health," said M. Susan Hardwick, President and CEO of American Water. American Water also joins other water organizations urging the U.S. EPA, Congress, and other decision-makers to implement policies that will exempt all water and wastewater systems from financial liability for PFAS under CERCLA.

06:18 EDT Infosys, Intel expand collaboration to accelerate generative AI - Infosys (INFY) and Intel (INTC) announced that they have expanded their strategic collaboration to assist global enterprises in accelerating their AI journeys. The advanced artificial intelligence, or AI, solutions offered as a part of this collaboration will aim to help businesses become cost effective and performance driven while being responsible by design.

06:09 EDT BlackBerry, ETAS to jointly sell and market software solutions - ETAS and BlackBerry QNX, a business unit of BlackBerry, have signed a contract to jointly sell and market software solutions accelerating the development of safety-critical functions for next generation software-defined vehicles. Through this new re-selling partnership, both companies will provide pre-integrated software leveraging ETAS middleware RTA-VRTE based on AUTOSAR Adaptive, and the QNX Operating System to provide a high performance and safe foundation for the development of microprocessor-based vehicle computer/domain controller electronic control units.

06:04 EDT Immuron reports Travelan sales - Sales Highlights: Global FYTD Mar 2024 AUD$3.6M, up 154% on (prior comparative period) pcp. Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter. Australia: FYTD Mar 2024 AUD$2.8M, up 234% on pcp. Mar 2024 Quarter AUD$0.9M, up 66% on pcp and 99% on last quarter. USA: FYTD Mar 2024 AUD$0.8M, up 35% on pcp. Mar 2024 Quarter AUD$0.3M, up 7% on pcp and 18% on last quarter. Sales commenced on Walmart.com. Flavio Palumbo, Chief Commercial Officer said "We continue to be excited by the strong sales results on Travelan. Immuron's investment to drive awareness of the Travelan brand has seen continued strong sales results in Australia. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring (Mar-May) / summer (Jun-Aug) vacation peak period."

05:58 EDT Bayer, Google Cloud partner on AI-powered healthcare product for radiologists - Bayer (BAYRY) and Google Cloud (GOOGL) on Tuesday announced a collaboration on the development of artificial intelligence solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will further develop its platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud's technology, including its generative AI tools. "Radiology plays a vital role in healthcare, and the need to efficiently and accurately uncover insights and deliver solutions at scale that can improve patient outcomes has never been greater," said Nelson Ambrogio, president, Radiology at Bayer. "Through the collaboration with Google Cloud, our joint efforts will help organizations in the healthcare and life science industry transform the growing amounts of data into valuable and impactful insights, saving radiologists time and helping them optimize their important work for the benefit of patients."

05:26 EDT Rio Tinto to partner with Founders Factory to invest A$14.4M in startups - Rio Tinto is teaming up with a global venture studio and start-up investor to back the development and commercialization of breakthrough technologies in the mining industry. Rio Tinto will partner with Founders Factory and invest A$14.4M in global pre-seed and seed stage start-ups over the next three years. The focus will be on technologies in the fields of safe mine operations, decarbonization, exploration processing and automation. Each start-up will receive a cash investment and participate in a four-month accelerator program run by Founders Factory to support product development and commercialization. The Western Australian Government has also partnered with Founders Factory to invest in nature-tech start-ups that preserve and restore nature and biodiversity. The partnerships with Rio Tinto and the Western Australian Government will support the first Australian hub of Founders Factory in Perth, Western Australia, boosting the state's innovation credentials. Founders Factory successfully operates in London, Johannesburg, Milan, Berlin, Bratislava, New York and Singapore.

05:19 EDT Philips Respironics reaches agreement with U.S. government on consent decree - Following the FDA's inspection of Philips Respironics' facility in Murrysville in 2021 and the subsequent inspectional observations, the U.S. Department of Justice, or DOJ, representing the FDA, began discussions with Royal Philips in July 2022 regarding the terms of a proposed consent decree. On January 29, Philips announced that it agreed with the DOJ and FDA on the terms of the proposed consent decree. Philips' subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA, that primarily focuses on Philips Respironics' business operations in the U.S., including its manufacturing facilities in Murrysville and New Kensington, its service center in Mount Pleasant and its Respironics headquarters in Pittsburgh in Pennsylvania. The consent decree provides Philips Respironics with a roadmap of defined actions, milestones, and deliverables to meet relevant regulatory requirements, as previously communicated by Philips on January 29, including: Philips Respironics will continue to prioritize completing the remediation of the sleep and respiratory care devices under Respironics' voluntary June 2021 recall. More than 99% of the actionable registered CPAP and BiPAP sleep therapy devices have been remediated globally, while the remediation of the ventilators is ongoing in coordination with the relevant competent authorities. Philips Respironics will retain independent experts to review various aspects of the recall remediation. Philips Respironics' business operations must demonstrate continued compliance with the FDA's Quality System Regulation. Philips Respironics will retain independent experts to supervise the compliance improvement program. In the U.S., millions of patients are currently using Philips Respironics sleep and respiratory care devices. Philips Respironics will be permitted to continue servicing these sleep and respiratory care devices that are already with healthcare providers and patients, and to sell accessories, consumables, and replacement parts. In 2021, Philips Respironics voluntarily stopped selling CPAP and BiPAP sleep therapy devices and other respiratory care devices in the U.S., as it prioritized the production for the remediation of the affected devices under the June 2021 recall. Until the relevant requirements of the consent decree are met, Philips Respironics will not resume selling new CPAP or BiPAP devices or other respiratory care devices in the U.S. The consent decree includes provisions to allow for exports. Outside the U.S., Philips Respironics will continue to provide new sleep and respiratory care devices, accessories, consumables, replacement parts and services, subject to certain requirements that Philips Respironics will meet. Philips Respironics' devices with the new silicone sound abatement foam have been subject to extensive testing in accordance with the applicable industry testing standards, and Philips Respironics has not identified any safety issues. These devices may continue to be used in accordance with the instructions for use. As previously stated on January 29, as a consequence of addressing this consent decree, which is a multi-year plan, Philips expects costs of around 100 basis points in 2024 that relate to remediation activities and profit disgorgement payments for Philips Respironics sales in the U.S. The previously stated 2023-2025 Group financial outlook of mid-single-digit comparable sales growth, low-teens Adjusted EBITA margin, and EUR 1.4-1.6 billion free cash flow now takes the consent decree into account and remains unchanged. It excludes the investigation by the U.S. DOJ related to the Respironics field action and the impact of the ongoing litigation.

05:06 EDT XPeng announces entry into Hong Kong, Macau - XPeng expanded its footprint through a dealer partnership with Sime Darby Motors in Hong Kong. The partnership will enable XPeng to bring its latest smart EVs to local consumers in the Hong Kong market with branded showrooms, after-sales support, and guidance through each stage of the buying process. As XPeng Motors officially enters Hong Kong, Sime Darby Motors has announced that XPeng focus models, including the latest pure electric SUV model G6 and the flagship pure electric seven-seater MPV X9, will be the first to meet with car fans in mid-May, and expected delivery starting from Q3. Alongside Hong Kong, XPeng is also set to enter Macau with partner Xin Kang Heng, offering XPeng models G9, X9, G6, and P7i. Left-hand drive models will start delivery in May.